OR-GUROBI-OPTIMIZATION
19.3.2024 15:20:34 CET | Business Wire | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced that its solver helps power CrewVision, the innovative tool developed by KLM Royal Dutch Airlines (KLM) in partnership with Boston Consulting Group (BCG) to facilitate long-term crew planning for airlines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319466107/en/
Courtesy: KLM Royal Dutch Airlines (KLM)
CrewVision makes it easy to create optimal five-year crew plans while accounting for critical factors, such as changes in industry regulations, fleets, hiring needs, and training requirements—a significant improvement from their previous outlook of nine months. With support from Gurobi’s solver, these five-year plans can now be generated within several hours, as opposed to an entire week. This allows KLM to spend more time strategizing around their long-term vision.
Prior to developing CrewVision, KLM used a legacy system to run analyses, with data spread across multiple sources. A total cycle took a week to process overall. With CrewVision, this is reduced to several hours.
“The nice thing about Gurobi is that we can easily experiment with different parameters and thresholds. We can do a lot of different runs to see what is still acceptable. So even though we have expanded the problem a lot, we can still go in and quickly get results that are quite good,” shares Tim Lamballais Tessensohn, Data Scientist at KLM.
This has dramatically increased the speed of their decision-making process, while allowing them to run 20-30 planning scenarios per week. Before using Gurobi, they would typically run just one.
In addition to navigating pilot shortages, they’d next like to use CrewVision to tackle other challenges, including shortages of ground personnel, engineers, and maintenance technicians.
“I think we now have a more dynamic response to volatility in the market,” says Lucille Witmans, KLM’s Senior Account Manager for the partnership with BCG. “We can now plan for a range of scenarios, instead of balancing for a single scenario.”
“Gurobi is proud to empower KLM with the tools to not only envision but also execute a more dynamic, responsive approach to airline operations. This success story is a testament to the power of decision intelligence technology in revolutionizing how airlines operate and plan for the future,” said Duke Perrucci, CEO of Gurobi Optimization.
To learn more about how Gurobi helps KLM create optimal, long-term crew plans in just a few hours, visit the case study page.
About the KLM-BCG Partnership
KLM Royal Dutch Airlines (KLM) and Boston Consulting Group (BCG) combine the best expertise in airline operations management to provide a best-in-class solution for business transformation and offer front-line operations teams AI-based solutions that provide full transparency—in real time—about the impact of every business decision. To learn more, visit www.airlineoperations.ai.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, customers can make optimal business decisions in seconds. From workforce scheduling and portfolio optimization to supply chain design and everything in between, Gurobi identifies the optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as over 80% of the world’s leading enterprises. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319466107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom